Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
28 Maio 2024 - 8:39PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 3)
Carisma
Therapeutics Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
14216R 101
(CUSIP
Number)
HealthCap VII, L.P.
Represented by HealthCap VI GP S.A.
23 Avenue Villamont
Lausanne, Switzerland CH-1005
+4121 614 3500
(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)
May 28, 2024
(Date of Event Which Requires Filing of this Statement)
If the filing
person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g) check the following box ☐.
* |
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form
with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of
the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).
|
|
|
|
|
|
|
1 |
|
Names of Reporting Persons
HealthCap VII, L.P. |
2 |
|
Check the Appropriate Box if a
Member of a Group (a) ☐ (b) ☒
|
3 |
|
SEC Use Only
|
4 |
|
Source of Funds
WC |
5 |
|
Check Box if Disclosure of
Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e):
☐ |
6 |
|
Citizenship or Place of
Organization
Delaware |
|
|
|
|
|
|
|
Number of
Shares
Beneficially
Owned by Each
Reporting Person
With: |
|
7 |
|
Sole Voting Power
3,398,248 |
|
8 |
|
Shared Voting Power
0 |
|
9 |
|
Sole Dispositive Power
3,398,248 |
|
10 |
|
Shared Dispositive Power
0 |
|
|
|
|
|
|
|
11 |
|
Aggregate Amount Beneficially Owned by Each Reporting Person
3,398,248 |
12 |
|
Check if the Aggregate Amount
in Row (11) Excludes Certain Shares ☐ |
13 |
|
Percent of Class Represented by
Amount in Row (11) 8.2% |
14 |
|
Type of Reporting Person
PN |
|
|
|
|
|
|
|
1 |
|
Names of Reporting Persons
HealthCap VII GP LLC |
2 |
|
Check the Appropriate Box if a
Member of a Group (a) ☐ (b) ☒
|
3 |
|
SEC Use Only
|
4 |
|
Source of Funds
AF |
5 |
|
Check Box if Disclosure of
Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e):
☐ |
6 |
|
Citizenship or Place of
Organization
Delaware |
|
|
|
|
|
|
|
Number of
Shares
Beneficially
Owned by Each
Reporting Person
With: |
|
7 |
|
Sole Voting Power
3,398,248 |
|
8 |
|
Shared Voting Power
0 |
|
9 |
|
Sole Dispositive Power
3,398,248 |
|
10 |
|
Shared Dispositive Power
0 |
|
|
|
|
|
|
|
11 |
|
Aggregate Amount Beneficially Owned by Each Reporting Person
3,398,248 |
12 |
|
Check if the Aggregate Amount
in Row (11) Excludes Certain Shares ☐ |
13 |
|
Percent of Class Represented by
Amount in Row (11) 8.2% |
14 |
|
Type of Reporting Person
PN |
Item 4. Purpose of Transaction
Item 4 of the Schedule 13D is hereby amended and supplemented as follows:
Representatives of HealthCap VII Advisor AB, the advisor of the Reporting Persons, have, together with representatives of the
Reporting Persons, engaged, and may continue to engage, with the Issuers management team regarding whether the Issuer should consider financing options, and if so, the timing and potential structure of such financing options,
including, but not limited to, sales of the Issuers equity securities.
Item 5. Interest in Securities of the Issuer
Item 5 of the Schedule 13d is hereby amended and supplemented as follows:
(a)-(b): The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage
set forth in row 13 is based on approximately 41,542,744 shares of Common Stock outstanding as of May 7, 2024, as reported in the Issuers Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024.
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this
statement is true, complete and correct.
Dated: May 28, 2024
|
|
|
HEALTHCAP VII, L.P.
By: HealthCap VII GP LLC, its general partner
By: HealthCap VI GP SA, its investment manager |
|
|
By: |
|
/s/ Dag Richter |
Name: |
|
Dag Richter |
Title: |
|
Director |
|
|
By: |
|
/s/ Fabrice Bernhard |
Name: |
|
Fabrice Bernhard |
Title: |
|
General Manager |
|
|
|
HEALTHCAP VII GP LLC
By: HealthCap VI GP SA, its investment manager |
|
|
By: |
|
/s/ Dag Richter |
Name: |
|
Dag Richter |
Title: |
|
Director |
|
|
By: |
|
/s/ Fabrice Bernhard |
Name: |
|
Fabrice Bernhard |
Title: |
|
General Manager |
Carisma Therapeutics (NASDAQ:CARM)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Carisma Therapeutics (NASDAQ:CARM)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024